AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH RECOMBINANT HUMAN GAMMA-INTERFERON
Authors: SMALL EJ WEISS GR MALIK UK WALTHER PJ JOHNSON D WILDING G KUZEL T BEJAMONDE A PATON V
Citation: Ej. Small et al., THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH RECOMBINANT HUMAN GAMMA-INTERFERON, The cancer journal from Scientific American, 4(3), 1998, pp. 162-167
RELATION BETWEEN LITERACY, RACE, AND STAGE OF PRESENTATION AMONG LOW-INCOME PATIENTS WITH PROSTATE-CANCER
Authors: BENNETT CL FERREIRA MR DAVIS TC KAPLAN J WEINBERGER M KUZEL T SEDAY MA SARTOR O
Citation: Cl. Bennett et al., RELATION BETWEEN LITERACY, RACE, AND STAGE OF PRESENTATION AMONG LOW-INCOME PATIENTS WITH PROSTATE-CANCER, Journal of clinical oncology, 16(9), 1998, pp. 3101-3104
MULTICENTER PHASE-II TRIAL OF INTERLEUKIN-2, INTERFERON-ALPHA, AND 13-CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: STADLER WM KUZEL T DUMAS M VOGELZANG NJ
Citation: Wm. Stadler et al., MULTICENTER PHASE-II TRIAL OF INTERLEUKIN-2, INTERFERON-ALPHA, AND 13-CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, Journal of clinical oncology, 16(5), 1998, pp. 1820-1825
TOPOTECAN IN PREVIOUSLY TREATED ADVANCED UROTHELIAL CARCINOMA - AN ECOG PHASE-II TRIAL
Authors: WITTE RS MANOLA J BURCH PA KUZEL T WEINSHEL EL LOEHRER PJ
Citation: Rs. Witte et al., TOPOTECAN IN PREVIOUSLY TREATED ADVANCED UROTHELIAL CARCINOMA - AN ECOG PHASE-II TRIAL, Investigational new drugs, 16(2), 1998, pp. 191-195
QUALITY-OF-LIFE IN METASTATIC PROSTATE-CANCER AMONG MEN OF LOWER SOCIOECONOMIC-STATUS - FEASIBILITY AND CRITERION-RELATED VALIDITY OF 3 MEASURES
Authors: KNIGHT SJ CHMIEL JS KUZEL T SHARP L ALBERS M FINE R MORAN EM NADLER RB SHARIFI R BENNETT CL
Citation: Sj. Knight et al., QUALITY-OF-LIFE IN METASTATIC PROSTATE-CANCER AMONG MEN OF LOWER SOCIOECONOMIC-STATUS - FEASIBILITY AND CRITERION-RELATED VALIDITY OF 3 MEASURES, The Journal of urology, 160(5), 1998, pp. 1765-1769
ADJUVANT AUTOLYMPHOCYTE THERAPY IN THE TREATMENT OF T-(1-3A,B,C) OR T-4N-CELL CARCINOMA(M0 RENAL)
Authors: SAWCZUK I ARMENTROUT S BABAYAN R GRAHAM S HOLDEN S KLAMET J KUZEL T LEONG S SMITH JA WHITE C
Citation: I. Sawczuk et al., ADJUVANT AUTOLYMPHOCYTE THERAPY IN THE TREATMENT OF T-(1-3A,B,C) OR T-4N-CELL CARCINOMA(M0 RENAL), The Journal of urology, 159(5), 1998, pp. 653-653
RANDOMIZED, CONTROLLED TRIAL OF EX-VIVO ACTIVATED T-CELLS VS. INTERFERON-ALPHA IN METASTATIC RENAL-CANCER
Authors: SAWCZUK I PETRYLAK D BENEDETTO P BERRIS R BUKOWSKI R DREICER R EINSTEIN A ELLERHORST J GOODMAN G GRAHAM S HARRIS D KEMPF R KLAMET J KUZEL T LEONG S LOGAN T MEYERS F MILLER W MURPHY B MCCAFFREY R WALTHER P WILLIAMS D HAWKINS M
Citation: I. Sawczuk et al., RANDOMIZED, CONTROLLED TRIAL OF EX-VIVO ACTIVATED T-CELLS VS. INTERFERON-ALPHA IN METASTATIC RENAL-CANCER, The Journal of urology, 159(5), 1998, pp. 740-740
ASSESSING QUALITY-OF-LIFE AND UTILITIES IN METASTATIC PROSTATE-CANCER
Authors: KNIGHT SJ CHMIEL JS ELSTEIN A KUZEL T NADLER RB FALCONE D SHARP L YANG T ALBERS M FINE R MORAN E SHARIFI R BENNETT CL
Citation: Sj. Knight et al., ASSESSING QUALITY-OF-LIFE AND UTILITIES IN METASTATIC PROSTATE-CANCER, The Journal of urology, 159(5), 1998, pp. 994-994
PHASE-II STUDY OF SINGLE-AGENT GEMCITABINE IN PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC UROTHELIAL CANCER
Authors: STADLER WM KUZEL T ROTH B RAGHAVAN D DORR FA
Citation: Wm. Stadler et al., PHASE-II STUDY OF SINGLE-AGENT GEMCITABINE IN PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC UROTHELIAL CANCER, Journal of clinical oncology, 15(11), 1997, pp. 3394-3398
A COMPARISON OF PERSPECTIVES ON PROSTATE-CANCER - ANALYSIS OF UTILITYASSESSMENTS OF PATIENTS AND PHYSICIANS
Authors: BENNETT CL CHAPMAN G ELSTEIN AS KNIGHT SJ NADLER RB SHARIFI R KUZEL T
Citation: Cl. Bennett et al., A COMPARISON OF PERSPECTIVES ON PROSTATE-CANCER - ANALYSIS OF UTILITYASSESSMENTS OF PATIENTS AND PHYSICIANS, European urology, 32, 1997, pp. 86-88
A PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY
Authors: DREICER R PROPERT KJ KUZEL T KIRKWOOD JM ODWYER PJ LOEHRER PJ
Citation: R. Dreicer et al., A PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY, American journal of clinical oncology, 20(3), 1997, pp. 251-253
IMMUNOPHENOTYPIC COMPARISON OF REACTIVE DERMATOSES, ATYPICAL LYMPHOIDINFILTRATES AND MYCOSIS-FUNGOIDES
Authors: HUSSONG J FANG J GUITART J ROSEN S KUZEL T ROENIGK H VARIAKOJIS D
Citation: J. Hussong et al., IMMUNOPHENOTYPIC COMPARISON OF REACTIVE DERMATOSES, ATYPICAL LYMPHOIDINFILTRATES AND MYCOSIS-FUNGOIDES, Laboratory investigation, 76(1), 1997, pp. 743-743
METASTATIC ADENOCARCINOMA OF THE PROSTATE TO THE ORBIT AS A PRESENTING SYMPTOM
Authors: GONZALEZ CM KUZEL T CARTER MA
Citation: Cm. Gonzalez et al., METASTATIC ADENOCARCINOMA OF THE PROSTATE TO THE ORBIT AS A PRESENTING SYMPTOM, The Journal of urology, 157(2), 1997, pp. 625-625
MYCOSIS-FUNGOIDES, HUMAN T-CELL LEUKEMIA-VIRUS AND O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE - ANY CONNECTION
Authors: YAROSH D DOLAN ME BELANICH M MCRAE B VANSEVENTER G PEZEN D KUZEL T
Citation: D. Yarosh et al., MYCOSIS-FUNGOIDES, HUMAN T-CELL LEUKEMIA-VIRUS AND O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE - ANY CONNECTION, Journal of investigative dermatology, 108(4), 1997, pp. 287-287
CHANGES IN QUALITY-OF-LIFE (QOL) FOR PATIENTS (PTS) ENROLLED IN A PHASE-III TRIAL OF TREATMENT WITH A DIPHTHERIA-TOXIN FUSION PROTEIN (DAB(389)IL-2) FOR MYCOSIS-FUNGOIDES (MF)
Authors: LIEPA A BENNETT CL YARNOLD PR ENAS N LOZANO J KUZEL T OLSON E MARTIN A KIM Y DUVIC M FRANKEL A VONDERHEID E BOWEN G JEGASOTHY B WOOD G GORDON M PINTERBROWN L FIVENSON D HEALD P OSCROFF A FOSS F GLODE M STEWART S MOLINA A KNOBLER E NICHOLS J
Citation: A. Liepa et al., CHANGES IN QUALITY-OF-LIFE (QOL) FOR PATIENTS (PTS) ENROLLED IN A PHASE-III TRIAL OF TREATMENT WITH A DIPHTHERIA-TOXIN FUSION PROTEIN (DAB(389)IL-2) FOR MYCOSIS-FUNGOIDES (MF), Blood, 90(10), 1997, pp. 3924-3924
ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR MYCOSIS-FUNGOIDES
Authors: KUZEL T TRAYNOR A ROSEN S VILLA M FISHMAN M BRUSH M BURT RK
Citation: T. Kuzel et al., ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR MYCOSIS-FUNGOIDES, Blood, 90(10), 1997, pp. 4498-4498
ANTIBODY AND PHARMACOKINETIC ANALYSIS FROM A PIVOTAL TRIAL OF ONTAK(TM) (DAB(389)IL-2) FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL)
Authors: BACHA P FOWLIE A GRIMALDO D HILLIER J OLSEN E MARTIN A KIM Y DUVIC M FRANKEL A VONDERHEID E BOWEN G JEGASOTHY B WOOD G GORDON M PINTERBROWN L FIVENSON D HEALD P OSEROFF A KUZEL T FOSS F GLODE M STEWART S MOLINA A KNOBLER E
Citation: P. Bacha et al., ANTIBODY AND PHARMACOKINETIC ANALYSIS FROM A PIVOTAL TRIAL OF ONTAK(TM) (DAB(389)IL-2) FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL), Blood, 90(10), 1997, pp. 1457-1457
PIVOTAL PHASE-III TRIAL OF 2 DOSE LEVELS OF DAB(389)IL-2 (ONTAK(TM)) FOR THE TREATMENT OF MYCOSIS-FUNGOIDES (MF)
Authors: KUZEL T OLSEN E MARTIN A KIM Y DUVIC M FRANKEL A VONDERHEID E BOWEN G JEGASOTHY B WOOD G GORDON M PINTERBROWN L FIVENSON D HEALD P OSEROFF A FOSS F GLODE M STEWART S MOLINA A KNOBLER E NICHOLS J BACHA P
Citation: T. Kuzel et al., PIVOTAL PHASE-III TRIAL OF 2 DOSE LEVELS OF DAB(389)IL-2 (ONTAK(TM)) FOR THE TREATMENT OF MYCOSIS-FUNGOIDES (MF), Blood, 90(10), 1997, pp. 2607-2607
PSEUDO-MYCOSIS FUNGOIDES IN A PATIENT TAKING CLONAZEPAM AND FLUOXETINE
Authors: GORDON KB GUITART J KUZEL T SALARD D BAKOUCHE O DOMER P ROENIGK H ROSEN S
Citation: Kb. Gordon et al., PSEUDO-MYCOSIS FUNGOIDES IN A PATIENT TAKING CLONAZEPAM AND FLUOXETINE, Journal of the American Academy of Dermatology, 34(2), 1996, pp. 304-306
PERFORMANCE-MEASUREMENT IN PROSTATE-CANCER CARE - BEYOND REPORT CARDS
Authors: ULLMAN M METZGER CK KUZEL T BENNETT CL
Citation: M. Ullman et al., PERFORMANCE-MEASUREMENT IN PROSTATE-CANCER CARE - BEYOND REPORT CARDS, Urology, 47(3), 1996, pp. 356-365
PHASE-1-2 CLINICAL-TRIAL SUPPORTS THE SAFETY AND EFFICACY OF TARGRETIN(TM) TOPICAL GEL, A NOVEL RXR-SELECTIVE RETINOID ANALOG, IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
Authors: BRENEMAN DL DUVIC M KUZEL T STEVENS V YOCUM R
Citation: Dl. Breneman et al., PHASE-1-2 CLINICAL-TRIAL SUPPORTS THE SAFETY AND EFFICACY OF TARGRETIN(TM) TOPICAL GEL, A NOVEL RXR-SELECTIVE RETINOID ANALOG, IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA, Blood, 88(10), 1996, pp. 2265-2265
GEMCITABINE IN THE TREATMENT OF PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA - A PHASE-II STUDY
Authors: KUZEL T STADLER W RAGHAVAN D LEVINE E VOGELZANG N ROTH B DORR FA
Citation: T. Kuzel et al., GEMCITABINE IN THE TREATMENT OF PATIENTS WITH ADVANCED TRANSITIONAL-CELL CARCINOMA - A PHASE-II STUDY, European journal of cancer, 31A, 1995, pp. 1152-1152
CLONAL CYTOGENETIC ABNORMALITIES IN PERIPHERAL-BLOOD LYMPHOCYTES OF PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA ARE ASSOCIATED WITH SHORTENED SURVIVAL
Authors: FINN WG THANGAVELU M YELAVARTHI KK PETERSON L KUZEL T SAMUELSON E RADEMAKER F ROSEN ST
Citation: Wg. Finn et al., CLONAL CYTOGENETIC ABNORMALITIES IN PERIPHERAL-BLOOD LYMPHOCYTES OF PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA ARE ASSOCIATED WITH SHORTENED SURVIVAL, Laboratory investigation, 72(1), 1995, pp. 110-110
PHASE-I TRIAL OF A DIPHTHERIA-TOXIN (DT) FUSION PROTEIN (DAB(389)IL-2) FOR THE TREATMENT OF INTERLEUKIN-2 RECEPTOR (IL-2R) EXPRESSING HEMATOLOGIC NEOPLASMS
Authors: KUZEL T FOSS F LEMAISTRE C PLATANIAS L RATAIN M ROOK A SALEH M SCHWARTZ G NICHOLS J
Citation: T. Kuzel et al., PHASE-I TRIAL OF A DIPHTHERIA-TOXIN (DT) FUSION PROTEIN (DAB(389)IL-2) FOR THE TREATMENT OF INTERLEUKIN-2 RECEPTOR (IL-2R) EXPRESSING HEMATOLOGIC NEOPLASMS, Blood, 86(10), 1995, pp. 1081-1081
2-CHLORODEOXYADENOSINE IS AN ACTIVE SALVAGE THERAPY IN ADVANCED INDOLENT NON-HODGKINS-LYMPHOMA
Authors: HOFFMAN M TALLMAN MS HAKIMIAN D JANSON D HOGAN D VARIAKOGIS D KUZEL T GORDON LI RAI K
Citation: M. Hoffman et al., 2-CHLORODEOXYADENOSINE IS AN ACTIVE SALVAGE THERAPY IN ADVANCED INDOLENT NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 12(4), 1994, pp. 788-792
Risultati: 1-25 | 26-32